| Today’s Big NewsJan 16, 2024 |
| By Gabrielle Masson,Annalee Armstrong,Max Bayer As the biotech industry attempts to claw its way out of a brutal bear market, investors are starting to pull their punches in preference for more sure bets. |
|
|
|
By Nick Paul Taylor Allakos is giving up on lirentelimab after the serial flop racked up another pair of failures. The biotech responded by laying off half of its employees, continuing the early-year upheaval that has seen Aclaris and TransCode Therapeutics part ways with their CEOs. |
By James Waldron As Alto Neuroscience’s machine learning-derived, biomarker-based depression therapies accrue positive phase 2 data, the company is planning to join the growing trickle of biotechs planning to IPO in early 2024. |
By James Waldron Genevant Sciences could be in line for up to $114.3 million as part of a deal to combine its lipid nanoparticle tech with Tome Biosciences’ programmable genomic integration expertise to develop an in vivo gene editing treatment for a rare liver disorder. |
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way, providing a robust and adaptable manufacturing platform for gene therapy breakthroughs.
|
|
By Nick Paul Taylor LegoChem Bioscience, fresh from fattening up on Johnson & Johnson’s cash, has found a way to feed its growing sweet tooth. Responding to the antibody-drug conjugate (ADC) sugar rush, the Korean biotech has secured 548.5 billion South Korean won ($411 million) from confectionery company Orion to support the expansion of its R&D pipeline. |
By James Waldron Disco Pharmaceuticals has arrived on the dancefloor with the backing of AbbVie’s VC arm and 20 million euros ($21.8 million) in seed financing to cut a rug with its lung and colorectal cancer candidates. |
By Helen Floersh A flu vaccine is the best shot at keeping influenza at bay, but it’s far from bulletproof against infection. But researchers have now discovered a potential way to prevent flu transmission that targets the host rather than the virus. |
By Helen Floersh Scientists have identified a plethora of previously-unidentified drug targets for breast cancer, cervical cancer, glioblastoma and more, thanks to the help of machine learning. |
By Angus Liu Since the FDA approved the first CAR-T therapy back in August 2017, high prices, small patients pools and limited manufacturing capacity have at times crippled these cell-based treatments. As biopharma companies clear those hurdles, a larger, more systemic problem now threatens the drug class. |
By Conor Hale First announced in June 2023, Illumina Ventures said the new genomics-focused funding and mentorship initiative would take over from its previous Accelerator program, while still offering new companies technical guidance and DNA analysis hardware through the sequencing giant. |
By Nick Paul Taylor People living with HIV are facing stigma, discrimination and comparatively low life satisfaction, according to a survey of more than 4,500 patients in the U.K. The survey shows medicines have transformed the management of the condition but other aspects of life with HIV are proving more resistant to change. |
By Paige Minemyer,Dave Muoio,Heather Landi,Noah Tong,Anastassia Gliadkovskaya We covered some of the biggest headlines from the four-day conference and after parsing through all the presentations, interviews and panel discussions, we tracked a handful of key trends dominating the conversations. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
